Crizotinib

SKU: C0699

Category: API's & Intermediates

Synonyms: (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine , PF 2341066 , PF-02341066 , PF02341066 , Xalkori; 877399-52-5
CAS-Number: C₂₁H₂₂Cl₂FN₅O
Molecular Formula: 450.34
Molecular Weight

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Identity: 1H-NMR
Appearance: White to off-white powder

Properties

Solvents: choroform, DMSO, methanol

Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.
Long Term Storage: +4°C
Short Term Storage: RT
Shipping: AMBIENT

Transportation: Packing Group III
RIDADR: UN 3077 9
Signal word: Warning
GHS Symbol: GHS07+GHS08+GHS09
Precautionary statements: P273-P280-P305 + P351 + P338
Hazard statements: H317-H319-H341-H400

Description: Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models| inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
References: (1) H.Y. Zou, et al., Cancer Res. 67, 4408 (2007) , (2) J.G. Christensen, et al., Mol. Cancer Ther. 6, 3314 (2007) , (3) J.J. Cui, et al., J. Med. Chem. 54, 6342 (2011) , (4) J. Tanizaki, et al., J. Thorac. Oncol. 6, 1624 (2011) , (5) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011) , (6) A.T. Shaw, et al., N. Engl. J. Med. 371, 1963 (2014)
InChi Key: KTEIFNKAUNYNJU-GFCCVEGCSA-N
Smiles: NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C)C4=C(Cl)C(F)=CC=C4Cl

Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models| inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.

Artikelnummer: C0699 Kategorie: API's & Intermediates

Zusätzliche Information

Zusätzliche Information

Synonyms	(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, PF 2341066, PF-02341066, PF02341066, Xalkori
Purity	≥98% (HPLC)
Appearance	White to off-white powder
CAS-Number	877399-52-5
Molecular Formula	C21H22Cl2FN5O
Molecular Weight	450.34
Identity	1H-NMR
Solvents	choroform, DMSO, methanol
Smiles	NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C)C4=C(Cl)C(F)=CC=C4Cl
InChi Key	KTEIFNKAUNYNJU-GFCCVEGCSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H317-H319-H341-H400
Precautionary statements	P273-P280-P305 + P351 + P338
GHS Symbol	GHS07+GHS08+GHS09
Signal word	Warning
RIDADR	UN 3077 9
Transportation	Packing Group III
References	(1) H.Y. Zou, et al., Cancer Res. 67, 4408 (2007), (2) J.G. Christensen, et al., Mol. Cancer Ther. 6, 3314 (2007), (3) J.J. Cui, et al., J. Med. Chem. 54, 6342 (2011), (4) J. Tanizaki, et al., J. Thorac. Oncol. 6, 1624 (2011), (5) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011), (6) A.T. Shaw, et al., N. Engl. J. Med. 371, 1963 (2014)
Quantity	10 mg, 50 mg, Bulk